Oren K. Fix

Oren K. Fix

Auto-generated profile, based on publicly available information

Oren K. Fix

Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Hepatology
Verified
Journal Article
Closed access
OFOren K. Fix
Oren K. Fix
BHBilal Hameed
Bilal Hameed
RFRobert J. Fontana
Robert J. Fontana
RKRyan M. Kwok
Ryan M. Kwok
BMBrendan M. McGuire
Brendan M. McGuire
RCRaymond T. Chung
Raymond T. Chung

12 February 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
OFOren K. Fix
Oren K. Fix
EBEmily A. Blumberg
Emily A. Blumberg
KCKyong‐Mi Chang
Kyong‐Mi Chang
JCJaime Chu
Jaime Chu
RCRaymond T. Chung
Raymond T. Chung
TGThe AASLD COVID‐19 Vaccine Working Group
The AASLD COVID‐19 Vaccine Working Group
The aim of this document is to provide a concise scientific review of the currently available COVID‐19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches. The anticipated use of COVID‐19 vaccines in patients with chronic liver disease (CLD) and liver transplant (LT) recipients is reviewed and practical guidance is provided for health care providers involved in the care of patients with liver disease and LT about vaccine prioritization and administration. The Pfizer and Moderna mRNA COVID‐19 vaccines are associated with a 94%‐95% vaccine efficacy compared to placebo against COVID‐19. Local site reactions of pain and tenderness were reported in 70%‐90% of clinical trial participants, and systemic reactions of fever and fatigue were reported in 40%‐70% of participants, but these reactions were generally mild and self‐limited and occurred more frequently in younger persons. Severe hypersensitivity reactions related to the mRNA COVID‐19 vaccines are rare and more commonly observed in women and persons with a history of previous drug reactions for unclear reasons. Because patients with advanced liver disease and immunosuppressed patients were excluded from the vaccine licensing trials, additional data regarding the safety and efficacy of COVID‐19 vaccines are eagerly awaited in these and other subgroups. Remarkably safe and highly effective mRNA COVID‐19 vaccines are now available for widespread use and should be given to all adult patients with CLD and LT recipients. The online companion document located at https://www.aasld.org/about‐aasld/covid‐19‐resources will be updated as additional data become available regarding the safety and efficacy of other COVID‐19 vaccines in development.

9 May 2021 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
AMAndrew M. Moon
Andrew M. Moon
BCBrenda Curtis
Brenda Curtis
PMPranoti Mandrekar
Pranoti Mandrekar
ASAshwani K. Singal
Ashwani K. Singal
EVElizabeth C. Verna
Elizabeth C. Verna
OFOren K. Fix
Oren K. Fix
The Coronavirus Disease 2019 (COVID‐19) pandemic has exacted a heavy toll on patients with alcohol‐associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of ALD and AUD was large and growing, even before the COVID‐19 pandemic. There is accumulating evidence that this pandemic has had a large direct effect on these patients and is likely to produce indirect effects through delays in care, psychological strain, and increased alcohol use. Now a year into the pandemic, it is important that clinicians fully understand the effects of the COVID‐19 pandemic on patients with ALD and AUD. To fill existing gaps in knowledge, the scientific community must set research priorities for patients with ALD regarding their risk of COVID‐19, prevention/treatment of COVID‐19, changes in alcohol use during the pandemic, best use of AUD treatments in the COVID‐19 era, and downstream effects of this pandemic on ALD. Conclusion: The COVID‐19 pandemic has already inflicted disproportionate harms on patients with ALD, and ongoing, focused research efforts will be critical to better understand the direct and collateral effects of this pandemic on ALD.

1 February 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BLBrian P. Lee
Brian P. Lee
GIGene Y. Im
Gene Y. Im
JRJohn P. Rice
John P. Rice
ALAnn Lazar
Ann Lazar
EWEthan Weinberg
Ethan Weinberg
NTNorah Terrault
Norah Terrault

25 March 2017
Verified
Dataset
Closed access
OFOren Fix
Oren Fix
The effect of electronic health records (EHRs) and increased regulatory requirements on physician time spent in patient care and related activities is carefully studied in this observational study funded by the American Medical Association. Trained observers documented the activities of 57 physicians from 16 practices in four states. The practice specialties included internal medicine, family medicine, cardiology and orthopedics. In addition to over 430 hours of observation during office hours, 21 physicians also self-reported after-hours work activity for seven consecutive days using a diary. The investigators found that, on average, for every office hour spent on direct clinical face time with patients, physicians spent almost two additional hours on EHR and other desk work. Less than one-third of the total office day was spent on direct clinical face time with patients while nearly half of the total office day was spent on EHR and desk work. Physicians also self-reported spending 1-2 hours of personal time at home each night using the EHR and on other work tasks. While this study did not collect data on physician burnout and dissatisfaction, the authors suggest that increasing demands associated with EHRs and other regulatory requirements have had unintended negative consequences including decreased time physicians spend engaging with patients.

21 May 2020 in Clinical Liver Disease
Verified
Journal Article
Open access
PDF file
OFOren K. Fix
Oren K. Fix
MSMarina Serper
Marina Serper
Click on the article title to read more.